In metabolic disorders, oral α-viniferin (20-40 mg/kg/day) improved lipid and glucose homeostasis in mice fed a high-fat diet, and it additionally improved liver and renal biomarkers such as blood urea nitrogen, creatinine, alanine aminotransferase, and aspartate aminotransaminase. The gene discussed is GPT; the disease is metabolic disease.